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Summary
Objectives: Fabry disease is caused by deﬁciency of -galactosidase A, and typically
causes multi-organ dysfunction. Patients with manifestations limited to the heart,
mainly left ventricular hypertrophy (LVH), have been reported as a disease variation.Hypertrophy We have reported a 3% prevalence of this cardiac variant in men with LVH, which we
designated ‘cardiac Fabry disease’. The purposes of this study were to evaluate the
terminal stage cardiac manifestations and autopsy ﬁndings in patients with cardiac
Fabry disease.
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Terminal stage cardiac ﬁndings in patients with cardiac
Methods: We examined seven
ing hospitalization, standard
and echocardiograms were
along with microscopic ﬁndin
Results: Six patients died of
trocardiograms revealed the
ventricular tachycardia. Ech
patients. Localized basal po
in the six patients who died
lar dysfunction. Histologicall
cells, showed glycosphingolip
organs or in systemic vascula
Conclusions: Severe left ven
bances and ventricular arrhyt
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ntroduction
abry disease is an X-linked recessive disorder
aused by mutation of the gene encoding -
alactosidase A (-gal A), one of the lysosomal
ydrolases [1]. In this disease, glycosphingolipids,
rimarily globotriaosylceramide, accumulate pro-
ressively in lysosomes of vascular endothelial cells
nd smooth muscle cells, as well as in various cells
n multiple organs, particularly the skin, kidneys,
nd heart [1]. Male patients with typical Fabry
isease show almost complete absence of -gal A
ctivity. They exhibit symptoms of angiokeratoma,
croparesthesia, hypohidrosis, and corneal opaci-
ies that develop in early childhood and eventually
ie from complications affecting the kidney, brain,
nd/or heart in their fourth or ﬁfth decade of
ife [1]. With respect to cardiac manifestations,
eft ventricular hypertrophy (LVH), valvular abnor-
alities, and electrocardiographic abnormalities,
ncluding arrhythmias, have been reported in many
atients [2—19].
Male patients with an atypical form of Fabry
isease with manifestations conﬁned to the heart
ave been described [20—24]. These patients with
his cardiac variant of Fabry disease have resid-
al -gal A activity, and the main manifestation
s LVH induced by excessive accumulation of gly-
osphingolipid in myocardial cells [1]. We have
eported that the cardiac variant of Fabry disease
as detected in 7 of 230 male patients (about 3%)
ith LVH [25]. All of those patients presented with
VH as the main ﬁnding, with the plasma -gal A
ctivity remaining at 4—14% of the normal activ-
ty and lacking the symptoms observed in typical
abry disease, such as angiokeratoma, acropares-
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terminal stage patients with cardiac Fabry disease. Dur-
12-lead electrocardiograms, Holter electrocardiograms,
obtained. Autopsies were performed and macroscopic
gs were evaluated.
heart failure and one of ventricular ﬁbrillation. Elec-
presence of conduction abnormalities and nonsustained
ocardiograms and autopsy ﬁndings revealed LVH in all
sterior wall thinning of the left ventricle was detected
of heart failure. All patients had severe left ventricu-
y, myocardial cells, but not cardiac vascular endothelial
id accumulation. No accumulation was observed in other
r endothelial cells.
tricular dysfunction with associated conduction distur-
hmias occur in patients with terminal stage cardiac Fabry
present and associated with thinning of the base of the
ll. In contrast to typical Fabry disease, accumulation of
ved in myocardial cells but not in other organs.
Cardiology. Published by Elsevier Ireland Ltd. All rights
hesia, hypohidrosis, and corneal opacity [25]. We
esignated this form of Fabry disease as ‘cardiac
abry disease’ and proposed that it represents a
ew clinical entity [26].
There have been few detailed reports on the his-
ologic ﬁndings of the heart and other organs in
atients with cardiac Fabry disease [20,21,23]. The
urposes of this study were to characterize the ter-
inal stage cardiac manifestations and histologic
ndings of the heart and other organs in autopsied
atients with cardiac Fabry disease.
ubjects and methods
atients studied
mong nine consecutive male patients with cardiac
abry disease who died between March 1992 and
ugust 2005 during hospitalization at our institu-
ion, seven autopsied patients were examined. The
iagnosis of cardiac Fabry disease was based on a
ow level of plasma -gal A activity, the presence of
VH, and the absence of clinical manifestations of
ypical Fabry disease such as angiokeratoma, acro-
aresthesia, hypohidrosis, and corneal opacity. Two
f the seven patients (Patients 5 and 6) received
nzyme replacement therapy.
lectrocardiography and echocardiography
uring hospitalization, standard 12-lead electro-
ardiograms (ECG), Holter ECG, and echocardio-
rams were obtained in all patients. The rhythm,
eart rate, PR interval, QRS duration, and SV1 +RV5
mplitude were evaluated in the standard 12-lead
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ECG. A PR interval≥ 0.21 s and a QRS dura-
tion≥ 0.12 s were considered as prolonged [27]. An
abnormal Q-wave was deﬁned as being 0.04 s or
longer in duration and ≥1/4 of the R-wave ampli-
tude in leads other than aVR. An SV1 +RV5 value
≥4.0mV was considered indicative of the presence
of left ventricular high voltage. In addition, Holter
ECG was performed to evaluate the type and sever-
ity of arrhythmias.
The interventricular septal wall thickness, left
ventricular posterior wall thickness, left atrial
dimension, left ventricular end-diastolic dimen-
sion, and left ventricular end-systolic dimension
were evaluated by M-mode echocardiography. An
interventricular septal wall or left ventricular
posterior wall thickness of ≥13mm was considered
diagnostic of hypertrophy [28]. A left atrial dimen-
sion of ≥41mm and a left ventricular end-diastolic
dimension of ≥58mm were considered to indicate
chamber enlargement [29]. A left ventricular
fractional shortening of ≤33% was considered
abnormal [29]. The presence or absence and
degree of abnormal left ventricular wall motion
were evaluated visually [30].
Histologic studies
After obtaining written informed consent from fam-
ily members, autopsies were performed. The heart,
kidneys, skin, liver, lung, spleen, pancreas, and
adrenal gland were obtained from six of the seven
patients (Patients 1—4, 6, and 7) for histologic
examination. Heart and kidneys only were obtained
from Patient 5 for histologic evaluation.
Heart tissue from each patient was ﬁxed in
10% buffered formalin, and the sections were
7
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Table 1 Clinical characteristics of seven patients with car
Patient number
1 2 3
Age at death (year) 68 66 63
Cause of death Heart
failure
Heart
failure
Heart
failur
Plasma -gal A
activity (nmol/h/ml) 1.2 1.0 1.3
% of normal 14 12 15
Coronary angiography Normal Normal Norm
Albuminuria (−) (−) (−)
Serum creatinine (mg/dl) 0.9 1.1 0.9
Cerebrovascular damage (−) (−) (−)
Angiokeratoma (−) (−) (−)
Acroparesthesias (−) (−) (−)
Hypohidrosis (−) (−) (−)
Corneal opacities (−) (−) (−)
(−), Absence of the ﬁnding.T. Takenaka et al.
tained with hematoxylin and eosin (H&E). In addi-
ion, cardiac specimens from ﬁve of the seven
atients (Patients 1—4, and 7) were examined
y osmium toluidine blue (TB) staining and elec-
ron microscopy. TB staining was performed on
hick sections from the block prepared for electron
icroscopy, which were ﬁxed in 3% glutaraldehyde
nd 2% paraformaldehyde. The tissue block for
lectron microscopy was dehydrated with ethanol
nd embedded in propylene oxide and epoxy resin
o prepare ultra-thin sections, which were stained
ith uranyl acetate and lead and evaluated by elec-
ron microscopy.
For the kidneys, H&E staining was performed
n samples from all of the patients using the
ethod described above, and TB staining was con-
ucted on samples from Patient 7. The skin, liver,
ung, spleen, pancreas, and adrenal gland samples
btained from six of the seven patients were eval-
ated by H&E staining (except Patient 5).
esults
linical characteristics
he clinical characteristics of the seven patients
re summarized in Table 1. The age at the time of
eath of the patients was 63—83 years. No blood
elationships were observed between the patients.
ll of the patients suffered cardiac death. Patient
died of ventricular arrhythmias and the other
ix patients died of heart failure. The plasma -
al A activity was 0.4—1.4 nmol/h/ml, which was
—17% of the normal control activity [25]. Coro-
diac Fabry disease
4 5 6 7
64 83 78 66
e
Heart
failure
Heart
failure
Heart
failure
Ventricular
ﬁbrillation
0.4 0.6 1.4 1.2
4 7 17 14
al Normal Normal Normal Normal
(−) (−) (−) (−)
1.1 1.2 1.0 1.2
(−) (−) (−) (−)
(−) (−) (−) (−)
(−) (−) (−) (−)
(−) (−) (−) (−)
(−) (−) (−) (−)
Terminal stage cardiac ﬁndings in patients with cardiac fabry disease 53
Table 2 Findings of electrocardiogram (ECG) and Holter ECG
Patient
number
Rhythm/HR
(beats/min)
PR QRS Holter ECG
Interval (s) Duration (s) Abnormal Q wave SV1 +RV5 (mV)
1 SR/90 0.24 0.20 (−) 2.2 Nonsustained VT
2 SR/72 0.26 0.18 (+) 4.1 Nonsustained VT
3 SR/83 0.22 0.20 (−) 2.6 Nonsustained VT
4 Paced/62 Paced Paced Paced Paced Nonsustained VT
5 Paced/86 Paced Paced Paced Paced Nonsustained VT
P
(
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p6 Paced/77 Paced Paced
7 SR/75 0.24 0.16
HR, heart rate; SR, sinus rhythm; VT, ventricular tachycardia;
ary angiograms performed at the time of diagnosis
howed normal coronary arteries in all of the
atients. No proteinuria was observed, and the
erum creatinine concentration was normal. None
f the patients had a history of cerebrovascular
isease, and none had evidence of angiokeratoma,
croparesthesia, hypohidrosis, or corneal opacity.
lectrocardiographic ﬁndings
he standard 12-lead ECG ﬁndings are shown in
able 2 and Fig. 1(A). Patient 4 had received a
DD pacemaker implantation because of sick sinus
yndrome. Patients 5 and 6 had received DDD
acemaker implantations because of complete atri-
E
T
a
igure 1 Electrocardiogram and echocardiogram obtained f
trioventricular block and intraventricular conduction disturba
al long-axis view (B) and short-axis view (C) show left vent
osterior wall of the left ventricle (indicated by arrows). Theaced Paced Nonsustained VT
−) 2.4 Nonsustained VT
absence of the ﬁnding; (+), presence of the ﬁnding.
ventricular block. The remaining four patients
howed normal sinus rhythm, but with ﬁrst degree
trioventricular block (PR interval, 0.22—0.26 s).
he four patients showed evidence of intraventric-
lar conduction disturbances with QRS intervals of
.16—0.20 s. Abnormal Q-waves were observed in
atient 2. Patient 2 also had left ventricular high
oltage (SV1 + RV5 = 4.1mV). Nonsustained ventric-
lar tachycardia was observed on the Holter ECGs
f all seven patients.chocardiographic ﬁndings
he echocardiographic ﬁndings are shown in Table 3
nd Fig. 1(B, C). All patients showed evidence of
rom Patient 1. Electrocardiogram (A) shows ﬁrst degree
nces. Two-dimensional echocardiograms in the paraster-
ricular hypertrophy with localized thinning of the basal
left atrium and left ventricle are enlarged.
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Table 3 Echocardiographic ﬁndings
Patient
number
IVSth
(mm)
LVPWth LAD (mm) LVDd (mm) LVDs (mm) FS (%) Left ventricular wall
motionBase (mm) Mid (mm)
1 17 7 14 51 71 61 14 Diffuse hypokinesis
Posterior akinesis
2 17 7 16 52 66 56 15 Diffuse hypokinesis
Posterior dyskinesis
3 16 5 16 47 72 67 7 Diffuse hypokinesis
Posterior akinesis
4 18 7 13 45 60 49 17 Diffuse hypokinesis
Posterior akinesis
5 14 4 13 48 64 52 19 Diffuse hypokinesis
Posterior akinesis
6 15 5 14 47 61 52 15 Diffuse hypokinesis
Posterior akinesis
7 20 20 20 34 49 38 22 Diffuse hypokinesis
tricul
end-
l
6
d
fIVSth, interventricular septal wall thickness; LVPWth, left ven
left ventricular end-diastolic dimension; LVDs, left ventricular
LVH with an interventricular septal wall thickness
of 14—20mm and a left ventricular posterior wall
thickness of 13—20mm. However, localized thin-
ning of the basal posterior wall of the left ventricle
was observed in six patients (except Patient 7).
The wall thickness of the thinned base of the left
ventricular posterior wall was 4—7mm. The left
atrial dimension was increased to 45—52mm in
six patients (except Patient 7). The left ventricu-
s
s
a
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Figure 2 Macroscopic ﬁndings of the hearts from Patients 1
both ventricles, with particularly marked left ventricular hype
failure had localized thinning at the base of the left ventricuar posterior wall thickness; LAD, left atrial dimension; LVDd,
systolic dimension; FS, fractional shortening.
ar end-diastolic dimension was also increased to
0—72mm in six patients (except Patient 7).
The fractional shortening of the left ventricle
ecreased to 7—22% in all of the patients. Dif-
use left ventricular hypokinesis was observed in all
even patients. In addition, Patients 1, 3—5 and 6
howed evidence of akinesis of the posterior wall,
nd Patient 2 showed evidence of dyskinesis of the
osterior wall.
(A), 2 (B), 3 (C), 4 (D), 5 (E) and 6 (F). Hypertrophy of
rtrophy, is present. These six patients who died of heart
lar posterior wall (indicated by arrows).
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ﬁerminal stage cardiac ﬁndings in patients with car
istologic studies of the heart
he heart weight in the seven patients was ele-
ated to 575, 655, 760, 688, 510, 534 and 520 g,
espectively. Hypertrophy of both ventricles was
bserved, along with marked LVH (Fig. 2). Dif-
use deposition of translucent white material was
bserved grossly in the myocardium in all of the
atients, and Patients 1—6 showed localized thin-
ing of the base of left ventricular posterior wall
Fig. 2). All patients showed no evidence of organic
tenosis of the coronary arteries.
Based on H&E staining, each patient had
arcoplasmic vacuolization and deciduation of
yocardial cells, with fatty inﬁltration and dif-
use ﬁbrosis of the stroma in the left ventricle
Fig. 3A—F). Similar ﬁndings were observed in
he right ventricle, left atrium, and right atrium,
lthough the changes were milder than those in
he left ventricle. The thinned region of the base
f the left ventricular posterior wall observed in
atients 1—6 showed marked ﬁbrosis with almost
o myocardial cells observed (Fig. 3G—L). In addi-
ion, the remaining myocardial cells showed severe
arcoplasmic vacuolization.
Based on TB staining, accumulation of stronglysmiophilic substance was observed in the vacuo-
ated regions identiﬁed by H&E staining, which was
onsistent with the staining pattern of glycosphin-
olipid that accumulates in Fabry disease (Fig. 4). In
s
c
p
t
igure 3 Light microscopic ﬁndings of the hearts from Patien
ased on hematoxylin and eosin staining (×100), all patients
A—F). The thinned region of the base of left ventricular pos
brosis, and almost no myocardial cells are observed (G—L).fabry disease 55
ddition, the degree of accumulation varied based
n location, with the left side of the heart show-
ng a higher degree of involvement than the right
ide of the heart. Based on electron microscopy,
ll patients examined showed increased lysosomal
nclusions with concentric lamellar conﬁgurations
haracteristic of Fabry disease affecting the cyto-
lasm of myocardial cells (Fig. 5).
The sarcoplasmic vacuolization observed with
&E staining was not seen in the coronary arteries
r blood vessels between myocardial cells (Fig. 6A).
ased on electron microscopy, no lysosomal inclu-
ions with concentric lamellar conﬁgurations were
bserved in cardiac capillary endothelial cells
Fig. 6B).
istologic ﬁndings of other organs
clerosis and atrophy of the kidneys was observed
rossly in six patients (except Patient 7), which
as thought to be due to peripheral circulatory
ailure caused by heart failure. Histologically, all
atients showed no evidence of sarcoplasmic vac-
olization in the endothelium or mesangial cells
f the glomerulus and renal tubules. In kidney tis-
ue from Patient 7, on which TB staining could be
onducted, no strongly osmiophilic substance was
resent in the endothelium or mesangial cells of
he glomerulus and renal tubules.
ts 1 (A, G), 2 (B, H), 3 (C, I), 4 (D, J), 5 (E, K) and 6 (F, L).
show sarcoplasmic vacuolization of the myocardial cells
terior wall observed in these six patients shows marked
56 T. Takenaka et al.
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wFigure 4 Light microscopic ﬁndings of the hearts from P
staining (×400), accumulation of strongly osmiophilic su
with glycosphingolipid accumulation.
In the skin samples, none of the patients showed
evidence of vacuolization in any component of the
epidermis, secretory epithelium of the sweat gland
in dermis, vascular endothelial cells, or ﬁbroblasts.
Concerning the liver, there was gross evidence of
‘nutmeg liver’-like congestion and sclerosis in the
patients who died of heart failure. Histologically,
all patients showed no evidence of sarcoplas-
t
a
i
w
Figure 5 Electron microscopic ﬁndings from the heart of Patie
with a concentric lamellar conﬁguration. The black bar indicats 1 (A), 2 (B), 3 (C), and 4 (D). Based on toluidine blue
nce is observed in myocardial cells, which is consistent
ic vacuolization in the hepatocytes, sinusoidal
ndothelial cells, or Kupffer cells. The lung wet
eight was increased in all patients and there
ere macroscopic ﬁndings consistent with conges-
ion and bleeding. Histologically, there was collapse
nd bleeding of alveolar cavities and intra-alveolar
nﬁltration of hemosiderin phagocytes consistent
ith pulmonary congestion. However, there was no
nt 1. Panels (A) and (B) show typical lysosomal inclusions
tes 3m in Panel (A), and 0.5m in Panel (B).
Terminal stage cardiac ﬁndings in patients with cardiac
Figure 6 Light and electron microscopic ﬁndings of
blood vessels between myocardial cells from Patient 1.
No sarcoplasmic vacuolization visualized by hematoxylin
and eosin staining is observed in the vascular endothelial
cells (A, indicated by arrow, ×200). Based on electron
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microscopy (B), no accumulation of lysosomal inclusions
n the capillary endothelial cell is observed (indicated by
rrow). The black bar indicates 3m (B).
arcoplasmic vacuolization characteristic of typi-
al Fabry disease in the lung. Although the spleen,
ancreas, and adrenal glands were examined, no
arcoplasmic vacuolization was observed.
iscussion
n male patients with cardiac Fabry disease,
bnormal ECG ﬁndings include sinus bradycardia,
ick sinus syndrome, atrial ﬁbrillation, shortened
R interval, atrioventricular block, intraventricu-
ar conduction disturbances, left ventricular high
oltage, abnormal Q-waves, ST-T changes, and pre-
ature ventricular contractions [20—24]. In male
atients with typical Fabry disease, sinus tachycar-
ia, sinoatrial block, supraventricular premature
ontractions, and supraventricular tachycardia
ave been reported in addition to the abnormal
w
a
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CG ﬁndings observed in male patients with cardiac
abry disease [2—7,9,11—23]. In the seven terminal
tage patients with cardiac Fabry disease described
n this study, sick sinus syndrome, atrioventricu-
ar block, intraventricular conduction disturbances,
nd abnormal Q-waves were observed. Addition-
lly, nonsustained ventricular tachycardia, which
as not previously been reported in cardiac Fabry
isease, was also observed. Despite the presence of
VH detected by echocardiography, left ventricular
igh voltage was observed only in one patient.
All male patients with cardiac Fabry disease
escribed so far have had LVH [20—24]. In male
atients with typical Fabry disease, Bass et al. [8]
escribed many patients with LVH, and Colucci et
l. [9] identiﬁed one patient with asymmetric sep-
al hypertrophy and stenosis of the left ventricular
utﬂow tract. In the seven patients with cardiac
abry disease in this study, moderate to severe LVH
as observed. In the setting of Fabry disease, gly-
osphingolipid accumulates in myocardial cells [1].
his accumulation is believed to be progressive, and
ay lead to LVH [8,13,15]. In this study, accumula-
ion was observed in myocardial cells in patients
ith cardiac Fabry disease, and this accumulation
ay be the cause of LVH.
In six of the seven patients with cardiac Fabry
isease in this study, localized thinning of the base
f the left ventricular posterior wall was detected
y echocardiography and conﬁrmed at the time of
utopsy. Histologically, the thinned region showed
vidence of deciduation and marked ﬁbrosis of
he myocardium. Moon et al. [31] reported using
adolinium-enhanced cardiovascular magnetic res-
nance that myocardial ﬁbrosis occurs in the base
f the left ventricular infero-lateral wall in patients
ith Fabry disease. Yet pathological evidence of
ocalized thinning of the base of the left ventricu-
ar posterior wall has not previously been reported
n Fabry disease, including cardiac Fabry disease.
ecause no signiﬁcant coronary artery stenoses
ere observed in any of the patients and no accu-
ulation was observed in the coronary arteries or
ardiac capillary endothelial cells, it is difﬁcult to
mplicate myocardial ischemia as a cause of the
hinning. Localized thinning of the base of left ven-
ricular posterior wall has similarly been reported
n patients with Duchenne muscular dystrophy [32].
ziner and Levin [32] hypothesized that the con-
truction of myocardium differs in different regions
f the left ventricular wall. Speciﬁcally, the run of
yocardial ﬁbers is net-like in the anterior wall,
hereas in the base of the posterior wall the ﬁbers
re parallel. It is hypothesized that the base of
he posterior wall becomes thin because of pres-
ure and volume overload caused by differences in
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the construction of the myocardial ﬁbers. In the
patients with cardiac Fabry disease in this study, it
is possible that localized thinning occurred at the
base of the left ventricular posterior wall through
a similar mechanism. We reported that appearance
of basal posterior left ventricular wall thinning is
an important echocardiographic ﬁnding that pre-
cedes heart failure in patients with cardiac Fabry
disease [33]. In contrast to the other six patients,
the one patient with no thinning at the base of
left ventricular posterior wall had no evidence of
enlargement of the left atrium or left ventricle,
and the left ventricular fractional shortening was
the greatest of the seven patients. It suggests that
localized thinning of the base of the left ventricular
posterior wall may be related to the severity of left
ventricular dysfunction.
With respect to left ventricular contractility in
male patients with cardiac Fabry disease, Elleder
et al. [20]. described a patient with hypokinesis of
the left ventricular posterior wall. Frustaci et al.
[24] described a male patient with cardiac Fabry
disease with hypokinesis of the midventricular and
apical walls and dyskinesis of the midventricular
inferior septum, with a decreased fractional short-
ening of 22%. In male patients with typical Fabry
disease, Bass et al. [8] reported that 4 of 22 patients
had decreased left ventricular contractility. All of
the patients in this present study had diffuse asyn-
ergy of the left ventricle with markedly reduced
left ventricular fractional shortening.
Among male patients with cardiac Fabry dis-
ease, no glycosphingolipid accumulation in the
coronary arteries or cardiac capillary endothelial
cells has been observed in histologic examina-
tions of the hearts of a total of three patients
[20,21,23]. However, in typical Fabry disease, it
has been reported that glycosphingolipid accu-
mulation occurs in coronary arteries, endothelial
cells, and smooth muscle cells of cardiac arteri-
oles and capillary endothelial cells [2,4,5,7,9,18].
In the seven patients with cardiac Fabry disease
in this study, no stenoses were identiﬁed by coro-
nary angiography. In addition, there were no light
microscopic ﬁndings of glycosphingolipid accumu-
lation in the coronary arteries or blood vessels
between myocardial cells, and no accumulation in
cardiac capillary endothelial cells was observed by
electron microscopy. In addition, there was no gly-
cosphingolipid accumulation in the kidneys, skin,
liver, lung, spleen, or adrenal gland. In the seven
patients with cardiac Fabry disease in this study,
accumulation of glycosphingolipid was observed in
myocardial cells but not in the coronary arter-
ies, cardiac arterioles, cardiac capillary endothelial
cells or other organs examined. Therefore, weT. Takenaka et al.
onﬁrmed that cardiac Fabry disease is a unique
athologic entity.
onclusions
he present study reports that severe left ven-
ricular dysfunction with associated conduction
isturbances and ventricular arrhythmias were
bserved in terminal stage patients with cardiac
abry disease. Autopsies of the patients revealed
he presence of LVH with localized thinning of
he base of the left ventricular posterior wall. In
ontrast to typical Fabry disease, accumulation of
lycosphingolipids occurs in myocardial cells but
ot in other organs.
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